885520-35-4

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-6-FLUORO (1H)INDAZOLE is used as a building block for the synthesis of pharmaceuticals, leveraging its unique chemical properties to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-6-FLUORO (1H)INDAZOLE serves as a key component in the creation of agrochemicals, potentially enhancing crop protection and yield through its incorporation into novel compounds.
Used in Medicinal Chemistry:
4-BROMO-6-FLUORO (1H)INDAZOLE is utilized in medicinal chemistry for its potential to form the basis of new drug candidates, thanks to its distinctive structural features and reactivity.
Used in Academic Research:
As a reagent in academic research, 4-BROMO-6-FLUORO (1H)INDAZOLE is employed for the preparation of a variety of organic compounds, facilitating advancements in organic synthesis and the discovery of new chemical entities.

InChI:InChI=1/C7H4BrFN2/c8-6-1-4(9)2-7-5(6)3-10-11-7/h1-3H,(H,10,11)

Downstream Products

• 1425932-79-1 1-(6-fluoro-1-methyl-1H-indazol-4-yl)ethanone 
• 1056263-61-6 4-bromo-6-fluoro-1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazole 
• 1056263-69-4 6-fluoro-1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazol-4-ol 
• 1056261-83-6 6-fluoro-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 

Relevant academic research and scientific papers

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.